ESPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Esperion Therapeutics has the Momentum Rank of 3.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Momentum Rank falls into.
Thank you for viewing the detailed overview of Esperion Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Warren | officer: Chief Commercial Officer | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
J Martin Carroll | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Sheldon L. Koenig | officer: Chief Operating Officer | C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Joanne M. Foody | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Benjamin Looker | officer: General Counsel | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Benjamin Halladay | officer: Chief Financial Officer | ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Alan Fuhrman | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Timothy M Mayleben | director, officer: Pres & Chief Executive Officer | 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Tracy M Woody | director | 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
Richard Bartram | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
From GuruFocus
By GlobeNewswire • 01-19-2024
By Marketwired • 08-26-2023
By Marketwired • 08-28-2023
By Marketwired • 08-08-2023
By Marketwired • 10-31-2023
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 06-28-2023
By sperokesalga sperokesalga • 05-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.